Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIND-014 in KRAS+ or Squamous NSCLC
NCT02283320Phase 2Completed
- Sponsor
- BIND Therapeutics
- Start
- Sep 2014
- Primary completion
- Apr 2016
- Modality
- Nanoparticles
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of BIND-014 in non-small cell lung cancer (NSCLC), sponsored by BIND Therapeutics. Primary endpoint: Disease Control Rate at 18 weeks. Started Sep 2014; status: completed.
02
Drugs
BIND-014
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02283320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02283320.